Yasmin Nabil Laimon

This study identifies fusion-driven oncogenic programs in translocation renal cell carcinoma (tRCC) that shape an immunosuppressive tumor microenvironment, explaining its reduced immunotherapy response.

This study investigates how transcription factor subtypes in small cell lung cancer influence response and resistance to DLL3-targeted therapy, revealing subtype-specific mechanisms of resistance.

This paper develops cyclin A/B macrocyclic inhibitors that induce apoptosis in cancers with high E2F activity by blocking RxL-mediated interactions, showing efficacy in SCLC models.

This study shows EED inactivation impairs SCLC tumorigenesis and drives LUAD-to-SCLC transformation, highlighting its role in maintaining SCLC neuroendocrine identity.

This study identifies TFE3 fusions driving OXPHOS in tRCC and reveals EGLN1 inhibition as a therapeutic target.

The paper identifies epigenomic signatures in sarcomatoid renal cell carcinoma (sRCC) that predict response to immune checkpoint inhibitors and are detectable in plasma, enabling non-invasive diagnosis.